A Patient-Centered Approach to Spravato Treatment and Medication Management
.png)
S pravato (esketamine), a nasal spray medication approved by the FDA in 2019, represents a new frontier in treatment-resistant depression (TRD). However, navigating Spravato therapy alongside existing medication regimens can be complex and requires a nuanced, patient-centered approach. This article delves into the crucial aspects of such an approach, ensuring successful outcomes for people struggling with TRD. Understanding TRD and Spravato: TRD, which affects about 30% of people with depression, presents a significant challenge. Traditional antidepressants often prove ineffective and leave people feeling hopeless and isolated. Spravato, with its unique mechanism of action targeting the NMDA receptor system, offers a ray of hope. It acts quickly, relieving depressive symptoms within hours in some cases, unlike traditional antidepressants, which can take weeks to show effect. The importance of a patient-centered approach Implementing a patient-centered approach to Spravato treatment and...